1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,311 | 0,330 | 23:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2026 | 127 | GlobeNewswire (Europe) | Quarter April-June 2026Net sales amounted to SEK 112.2 million (129.3), corresponding to a decrease of 13.3 percent. Organic sales growth amounted to -5.3 percent, currency effects amounted to -8.0... ► Artikel lesen | |
| 18.06. | Boule Diagnostics AB: Boule Diagnostics appoints new Chief Executive Officer | 624 | GlobeNewswire (Europe) | The Board of Directors at Boule Diagnostics has today appointed Johan Folkunger, Chief Executive Officer, effective June 22, 2026. Johan Folkunger succeeds Simonetta Tumbiolo, who has been serving... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 29.05. | Boule Diagnostics AB: Interim CEO at Boule Diagnostics | 151 | GlobeNewswire (Europe) | The board of directors at Boule Diagnostics has today appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as Interim Chief Executive Officer, effective June 1 2026. As previously... ► Artikel lesen | |
| 13.05. | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics | 269 | GlobeNewswire (Europe) | At the Annual General Meeting 2026 (the "AGM") it was resolved to adopt the balance sheets and profit and loss statements for the parent company and the group for the financial year 2025. The AGM resolved... ► Artikel lesen | |
| 28.04. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2026 | 164 | GlobeNewswire (Europe) | Stable start to 2026
Quarter January-March 2026} Net sales amounted to SEK 101.6 million (112.9), corresponding to a decrease of 10.0 percent. Organic sales growth amounted to 3.0 percent, currency... ► Artikel lesen | |
| 11.02. | Boule Diagnostics AB: Boule Diagnostics Year-end report 2025 | 364 | GlobeNewswire (Europe) | Improved operating cash flowQuarter October-December 2025Net sales amounted to SEK 120.2 million (143.2), corresponding to a decrease of 16.0 percent. Organic sales growth amounted to -11.7 percent... ► Artikel lesen | |
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 356 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 188 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 218 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen | |
| 24.10.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2025 | 282 | GlobeNewswire (Europe) | Back to organic growth Quarter July-September 2025Net sales amounted to SEK 127.2 million (130.4), corresponding to a decrease of 2.4 percent. Organic sales growth amounted to 1.7 percent, currency... ► Artikel lesen | |
| 13.10.25 | Boule Diagnostics AB: Boule Diagnostics Announces CFO Departure for New Opportunity | 202 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization.Torben Nielsen, CEO of Boule... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,650 | +5,16 % | Fresenius hebt nach dem zweiten Quartal den Ergebnisausblick an | ||
| FRESENIUS MEDICAL CARE | 41,310 | -0,36 % | Rallye bei Palantir: Rekordjagd geht weiter: DAX startet mit Gewinnen nach Zahlenreigen | © Foto: Arne Dedert/dpaEuropas Börsen haben am Dienstag weiter zugelegt. Starke Vorgaben und die Berichtssaison stützen die Rekordstimmung. Rallye bei Palantir, in Deutschland haben Bayer, Lufthansa... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,240 | +0,62 % | Siemens Healthineers Aktie: Diagnostik bremst, Auftragsbestand stützt | Nach den Zahlen zum dritten Geschäftsquartal und der angepassten Jahresprognose bleiben fünf Analystenhäuser bei überwiegend positiven Voten für die Siemens Healthineers Aktie. Die Kursziele bewegen... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,02 | +0,40 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 19,370 | +5,96 % | Jefferies senkt Kursziel für Procept BioRobotics nach verfehlten Eingriffszahlen | ||
| AUTONOMIX MEDICAL | 12,100 | -37,95 % | Morning Market Movers: Gran Tierra Energy, Autonomix Medical, Julong Holding, Shopify See Big Swings | OTTAWA (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BILLIONTOONE | 149,96 | +5,42 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| PACS GROUP | 45,630 | +1,72 % | Hohes Handelsaufkommen bei Optionen der Pacs Group | ||
| ALIGNMENT HEALTHCARE | 13,680 | +1,18 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| ADAPTHEALTH | 6,490 | -3,28 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 30,280 | -2,20 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| GENEDX | 69,95 | -1,71 % | Cathie Wood's ARK sells Palantir stock, buys GeneDx Holdings | ||
| BLUEJAY DIAGNOSTICS | 1,240 | +24,00 % | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study | ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today... ► Artikel lesen | |
| AGILON HEALTH | 107,62 | +13,31 % | agilon health, Inc. Announces Reverse Stock Split | WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL) (the "Company"), the trusted partner empowering physicians to transform health care in our communities, today announced that it will... ► Artikel lesen | |
| GERRESHEIMER | 26,360 | -3,51 % | Gerresheimer schließt Milliardendeal mit Apax | Gerresheimer trennt sich von seinem globalen Geschäft mit Kunststoff-Primärverpackungen und der US-Tochter Centor. Käufer sind von Apax Partners beratene Fonds, die dabei 15 Produktionsstandorte in... ► Artikel lesen |
Das Unternehmen BOULE DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,027 (-7,64 %) liegt der Kurs bei 0,321 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOULE DIAGNOSTICS AB finden Sie auf Wallstreet Online.